Brief: Monte Rosa Therapeutics Q4 Operating Income USD -49.715 Million
17/03/2026 11:00
Mar 17 (Reuters) - Monte Rosa Therapeutics Q4 operating expenses USD 52.496 million. Q4 collaboration revenue USD 2.781 million Q4 net income USD -46.135 million
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million